FORT WORTH, Texas, Sept. 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary, Wound Care Innovations, L.L.C. (WCI), signed a distribution agreement with Bivium International, LLC (Bivium) to distribute its advanced wound care collagen product, Cellerate RX® in Panama. Bivium International will be introducing Cellerate RX® to the Panamian health-care community at the Congress of the Panamanian Association of General Surgery conference from September 16th to the 18th in Panama City. The addition of Panama now puts WCI's distribution channels in 6 countries in Central America, to include Belize, El Salvador, Honduras, Nicaragua and Guatemala as the company continues to fulfill its targeted strategy which it outlined in May.
Cathy Bradshaw, President of WCI was quoted as saying, "We are extremely excited to see the growth of Cellerate RX® in the Central American region. Cellerate RX® is FDA cleared for use on all acute and chronic wounds except 3rd degree burns and so many will benefit from having it available. It has been found to be very effective in managing diabetic wounds, a problem in this region as well as throughout the world." Ronald Mathis, Senior Vice President of Marketing and Sales for WCI said, "Having been to Central America this year to participate in the clinical evaluation process, I am thrilled that Cellerate RX® now has a distribution partner for Panama to help speed the delivery of our product into the hands of the patients that need access to it the most."
When asked about the relationship with WCI, Moises Carvente, President of Bivium International was quoted: "Bivium is excited to be chosen as the distribution channel for Cellerate RX® into Panama. We look forward to a long and prosperous relationship with WCI and the expanding medical community within Panama."
For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on Cellerate RX®, please visit the WCI web site at http://www.celleraterx.com/.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com, and http://www.secureehealth.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Shareholder Relations-Communications (817)820-7077
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved